News Releases December 1, 2022 Ventyx Biosciences Announces Dosing of the First Patient in the Phase 2 SERENITY Trial of VTX958 for the Treatment of Moderate to Severe Plaque Psoriasis Read more November 22, 2022 Ventyx Biosciences to Participate in Two Upcoming Investor Conferences Read more November 3, 2022 Ventyx Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress Read more October 27, 2022 Ventyx Biosciences to Report Third Quarter 2022 Financial Results on November 3, 2022 Read more October 27, 2022 Ventyx Biosciences to Participate in Three Upcoming Investor Conferences Read more September 19, 2022 Ventyx Biosciences Announces $176.6 Million Private Placement of Common Stock Read more August 29, 2022 Ventyx Biosciences to Participate in Two Upcoming Investor Conferences Read more August 15, 2022 Ventyx Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress Read more August 15, 2022 Ventyx Biosciences Announces Positive Topline Phase 1 Data for Its Selective Allosteric TYK2 Inhibitor VTX958 Read more August 11, 2022 Ventyx Biosciences to Report Topline Results from the Phase 1 trial of its TYK2 Inhibitor VTX958 and Second Quarter 2022 Financial Results on August 15, 2022 Read more First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Next page › Last page » Displaying 11 - 20 of 33
